STRUCTURE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.29 USD | +0.77% |
|
+0.90% | -3.61% |
| 04-09 | Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target | MT |
| 03-21 | ADRs Edge Higher; Lufax Climbs Almost 46% | DJ |
| Sales 2024 * | - | Sales 2025 * | 28.57M 2.28B | Capitalization | 1.83B 146B |
|---|---|---|---|---|---|
| Net income 2024 * | -127M -10.13B | Net income 2025 * | -112M -8.93B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 345M 27.51B | Net cash position 2025 * | 150M 11.96B | EV / Sales 2025 * | 58.9 x |
| P/E ratio 2024 * |
-40.9
x | P/E ratio 2025 * |
-39.1
x | Employees | 93 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.77% | ||
| 1 week | +0.90% | ||
| Current month | -0.38% | ||
| 1 month | -0.03% | ||
| 3 months | -10.26% | ||
| 6 months | -43.78% | ||
| Current year | -3.61% |
1 week
37.85
41.13
1 month
35.5345.11
Current year
33.6550.73
1 year
21.7975.02
3 years
20.8075.02
5 years
20.8075.02
10 years
20.8075.02
| Managers | Title | Age | Since |
|---|---|---|---|
Raymond Stevens
FOU | Founder | 60 | 31/01/19 |
Jun Yoon
DFI | Director of Finance/CFO | 46 | 31/01/19 |
Ying Li Ma
CTO | Chief Tech/Sci/R&D Officer | 50 | 31/07/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sharon Tetlow
BRD | Director/Board Member | 64 | 28/03/22 |
Ted Love
BRD | Director/Board Member | 65 | 02/08/23 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 30/11/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 39.29 | +0.77% | 423,228 |
| 02/05/24 | 38.99 | -0.84% | 598,983 |
| 01/05/24 | 39.32 | -0.30% | 631,784 |
| 30/04/24 | 39.44 | +1.02% | 707,077 |
| 29/04/24 | 39.04 | +0.26% | 183,155 |
Delayed Quote Nasdaq, May 03, 2024 at 09:15 pm
More quotes
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
39.29
USD
Average target price
80.5
USD
Spread / Average Target
+104.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.61% | 1.83B | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- GPCR Stock
